F-LP/gDNMT1 effectively mutated endogenous DNMT1 in vitro and then expressed Cas9 endonuclease and downregulated DNMT1 in vivo in paclitaxel-sensitive and resistant ovarian cancers [97]. This evidence concerns the gene DNMT1 and ovarian carcinoma.